Synta to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference

Company to Webcast Presentation on March 14

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Roth Capital OC Growth Stock Conference on Monday, March 14 at 4:00 p.m. (PST) in Laguna Niguel, California.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.



CONTACT:

Synta Pharmaceuticals Corp.
tel: 781 541 7125
fax: 781 274 8228
www.syntapharma.com
or
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125

KEYWORDS:   United States  North America  California  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.